☆ 4.4 Article

Washed microbiota transplantation for Clostridioides difficile infection: A national multicenter real-world study

JOURNAL OF DIGESTIVE DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Pediatrics

Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013 to 2019

Price T. Edwards et al.

Summary: This study compared the incidence, epidemiology, testing patterns, treatment, and outcomes of Clostridioides difficile infection (CDI) among hospitalized pediatric patients from 2013 to 2019. The results showed a decreasing trend in CDI incidence and a higher proportion of patients with cancer and gastrointestinal conditions.

JOURNAL OF PEDIATRICS (2023)

Add to Collection

Article Infectious Diseases

Redefining Clostridioides difficile infection antibiotic response and clinical outcomes

Anne J. Gonzales-Luna et al.

Summary: With the approval and development of narrow-spectrum antibiotics for the treatment of Clostridioides difficile infection (CDI), the primary endpoint for treatment success of CDI antibiotic treatment trials has shifted from treatment response at end of therapy to sustained response 30 days after completed therapy. The current definition of a successful response to treatment (three or fewer unformed bowel movements [UBMs] per day for 1-2 days) has not been validated, does not reflect CDI management, and could impair assessments for successful treatment at 30 days. We propose new definitions to optimise trial design to assess sustained response. Primarily, we suggest that the initial response at the end of treatment be defined as (1) three or fewer UBMs per day, (2) a reduction in UBMs of more than 50% per day, (3) a decrease in stool volume of more than 75% for those with ostomy, or (4) attainment of bowel movements of Bristol Stool Form Scale types 1-4, on average, by day 2 after completion of primary CDI therapy (ie, assessed on day 11 and day 12 of a 10-day treatment course) and following an investigator determination that CDI treatment can be ceased.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection & nbsp;A Phase 3, Open-Label, Single-Arm Trial

Matthew D. Sims et al.

Summary: A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. This study evaluated the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks. The results showed that the rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.

JAMA NETWORK OPEN (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery

Gaochen Lu et al.

Summary: This study describes the methodology development of faecal microbiota transplantation (FMT) in China from manual to washing preparation, and provides insights into donor screenings, treatment doses, adverse events and delivery decisions. The success rate of donor screening was found to be 3.1%, and the incidence rate of fever decreased significantly with washed microbiota transplantation (WMT) in ulcerative colitis patients. The study also suggests a new definition for treatment units based on enriched microbiota and proposes a promising method for delivering microbiota through colonic transendoscopic enteral tube.

MICROBIAL BIOTECHNOLOGY (2022)

Add to Collection

Article Immunology

Washed microbiota transplantation improves patients with metabolic syndrome in South China

Lei Wu et al.

Summary: This study investigated the effects of washed microbiota transplantation (WMT) on metabolic syndrome (MS) patients in southern China. The results showed that WMT had a significant improvement effect on MS patients, including improvements in comprehensive efficacy and ASCVD risk, as well as improvements in gut microbiota.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Sahil Khanna et al.

Summary: RBX2660 is a safe and effective treatment option for reducing recurrent C. difficile infection following standard-of-care antibiotics, with a sustained response lasting up to 6 months.

DRUGS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Fecal microbiota transplantation may reduce the mortality of patients with severe and fulminant Clostridioides difficile infection compared to standard-of-care antibiotics in a community hospital

Maria Mironova et al.

Summary: This study aimed to evaluate the impact of FMT on the mortality rate of patients with severe and fulminant CDI. The results suggest that FMT may decrease the mortality of these patients. However, larger studies are needed to validate these findings.

JOURNAL OF DIGESTIVE DISEASES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial

Simon Mark Dahl Baunwall et al.

Summary: For patients with first or second C difficile infection, first-line faecal microbiota transplantation is highly effective and superior to standard vancomycin treatment in achieving sustained resolution of C difficile.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults

Joffrey van Prehn et al.

Summary: The document provides guidance on the treatment of Clostridioides difficile infection with a focus on the best treatment methods and factors influencing treatment strategies.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Immunology

Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital

Ren-feng Zhang et al.

Summary: This study identified and characterized five C. difficile 027 isolates in China, showing high resistance to fluoroquinolones. These isolates were confirmed through MLST, PCR ribotyping, and whole genome sequencing. The findings suggest that C. difficile 027 infections may be neglected in China, warranting further epidemiological studies nationwide.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2021)

Add to Collection

Article Infectious Diseases

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study

Sylvia Polivkova et al.

Summary: This study demonstrates that fidaxomicin is superior to metronidazole or vancomycin in the treatment of the initial episode, first recurrence, and non-severe cases of Clostridioides difficile infection.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Cell Biology

Geographic differences in gut microbiota composition impact susceptibility to enteric infection

Ana Maria Porras et al.

Summary: Large-scale studies of human gut microbiomes have shown broad differences in composition across geographically distinct populations, which may lead to varying levels of resistance to specific diseases. Experimenting with microbiome samples from donors representing different countries, researchers observed geographic differences in susceptibility of mice to specific bacterial infections. Further findings suggest that cohabitation of susceptible and resistant mice can enhance immunity to bacterial infections.

CELL REPORTS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: experience of a large-volume European FMT center

Gianluca Ianiro et al.

Summary: Inflammatory bowel disease (IBD) is a risk factor for C. difficile infection (CDI), and fecal microbiota transplantation (FMT) appears to be highly effective and safe in treating both CDI and improving disease activity of IBD.

GUT MICROBES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection

Jessica R. Allegretti et al.

Summary: This study explored the use of FMT in patients with IBD-CDI and found that it may lead to improvements in IBD outcomes among patients with Crohn's disease and ulcerative colitis. The study suggests that FMT could be a potential treatment option for these patients with recurrent CDI.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children

Maribeth R. Nicholson et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent Clostridioides difficile Infection

Colleen R. Kelly et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?

Liyuan Xiang et al.

MICROBIAL BIOTECHNOLOGY (2020)

Add to Collection

Article Cell Biology

Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening

Ting Zhang et al.

PROTEIN & CELL (2020)

Add to Collection

Article Medicine, General & Internal

Trends in US Burden of Clostridioides difficile Infection and Outcomes

Alice Y. Guh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Gastroenterology & Hepatology

Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes

Qianqian Li et al.

Clinical and Translational Gastroenterology (2020)

Add to Collection

Article Gastroenterology & Hepatology

Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection

Benjamin H. Mullish et al.

GUT (2019)

Add to Collection

Article Gastroenterology & Hepatology

High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: A prospective observational cohort study

Xiao Li Chen et al.

JOURNAL OF DIGESTIVE DISEASES (2019)

Add to Collection

Article Gastroenterology & Hepatology

International consensus conference on stool banking for faecal microbiota transplantation in clinical practice

Giovanni Cammarota et al.

GUT (2019)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence of Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the United States

Thomas Sommers et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection

Christian Lodberg Hvas et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Immunology

Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)

L. Clifford McDonald et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Letter Medicine, General & Internal

Fecal Microbiota Transplantation for Primary Clostridium difficile Infection

Frederik E. Juul et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Regional variation limits applications of healthy gut microbiome reference ranges and disease models

Yan He et al.

NATURE MEDICINE (2018)

Add to Collection

Article Immunology

Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

Marie Hocquart et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Review Gastroenterology & Hepatology

The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis

Taha Qazi et al.

GUT MICROBES (2017)

Add to Collection

Article Gastroenterology & Hepatology

Fecal microbiota transplant in severe and severe-complicated &ITClostridium difficile&IT: A promising treatment approach

Monika Fischer et al.

GUT MICROBES (2017)

Add to Collection

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection

Y. -T. Li et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)

Add to Collection

Article Gastroenterology & Hepatology

Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients

Colleen R. Kelly et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)

Add to Collection

Editorial Material Gastroenterology & Hepatology

The Role of Compassion in the Practice of Evidence-Based Medicine

Lynne V. McFarland

AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Fidaxomicin versus Vancomycin for Clostridium difficile Infection

Thomas J. Louie et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.